Vedolizumab, Empagliflozin And Vintafolide Receive Positive EU Opinions After CHMP Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.